Pfizer has sold 700 million shares in British consumer-healthcare business Haleon for 2.50 billion pounds, equivalent to US$3.05 billion, it said in a statement.

As a result, Pfizer will reduce its holding in Haleon to around 15% from around 22.6%. The settlement of both operations is expected to occur on Thursday, subject to certain conditions.

Pfizer will sell about 662 million ordinary shares, or 7.3%, of Haleon, created in a merger of GSK and Pfizer's consumer healthcare businesses in 2019, and spun off in 2022.

Sensodyne, the toothpaste first marketed in 1961 to reduce the pain of sensitive teeth, is among premium brands on sale in pharmacies and drug stores around the world. But if you live in an Indian ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer (NYSE: PFE) has generated £2.5B ($3.24B) after selling its entire stake in Haleon (NYSE: HLN), the consumer healthcare company it established with the British pharmaceutical giant GSK (GSK ...

Pfizer also sold around £170 million worth of shares back to Haleon in an off-market share repurchase transaction. Haleon shares were down 0.2% as of 8:38 a.m. in London on March 19 after ...

Pfizer Inc. has raised about £2.4 billion ($3.2 billion) from the sale of Haleon Plc shares, as it further reduces its stake in the UK consumer health company.

Pfizer will receive all of the net proceeds, while Haleon won't receive any. Write to Najat Kantouar at [email protected] (END) Dow Jones Newswires January 14, 2025 12:16 ET (17:16 GMT) ...

Pfizer will receive around 2.66 billion pounds ($3.56 billion) in aggregate from Haleon from an offering and a share buyback. Goldman Sachs International said Tuesday that the pharmaceutical ...

Pfizer has sold 700 million shares in British consumer-healthcare business Haleon for 2.50 billion pounds, equivalent to US$3.05 billion, it said in a statement.